Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,033.26
(
-1.30%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 162138

Monday, 07/15/2013 12:29:31 PM

Monday, July 15, 2013 12:29:31 PM

Post# of 257579
Ipsen—the maker of Dysport—announced two botulinum-toxin deals today: a research collaboration with Harvard University and the acquisition of private biotech firm, Syntaxin:

http://finance.yahoo.com/news/ipsen-announce-sponsored-research-agreement-050000844.html (Harvard)

http://finance.yahoo.com/news/ipsen-strengthens-neurology-r-d-050000369.html (Syntaxin)

The Syntaxin acquisition is for $37M with a $170M earn-out.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up